Health
Pfizer to spend $11.6B on migraine treatment maker Biohaven
Pfizer is spending more than $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own.
The New York drugmaker said Tuesday it will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has another nasal spray under development.
The price represents a 33 percent premium over Biohaven’s 90-day weighted average trading price of $111.70 for Biohaven Pharmaceutical Holding Co. Ltd., which is based in New Haven, Connecticut.
Shares of Biohaven, which had tumble below $100 in recent weeks, soared 72 percent before the opening bell to about $72. Pfizer’s stock slipped.
Pfizer Inc. has been flush with cash in recent quarters, thanks in part to sales of its COVID-19 vaccine Comirnaty and now its pill treatment for the virus, Paxlovid.
Portugal approves sale of Chelsea by Abramovich
U.S. making COVID antiviral drug more available at test sites
Spain to reform secret services after hacking of mobile phones of top politicians
Bulgaria uses police dogs in migrant pushbacks: Rights group
Taiwan raids Chinese firms in latest crackdown on chip engineer-poaching
-
Middle East2 weeks agoSaudi Arabia, US strengthen cooperation in technology, space as part of Vision 2030
-
Europe2 weeks agoAnother Russian naval ship is on fire in the Black Sea: Ukraine
-
Business1 week agoGlobal NFT spending on track to reach all-time high, with $37bn spent so far
-
Middle East1 week agoLebanon gets Interpol notice for Ghosn arrest: Source
-
Business2 weeks agoElon Musk says Twitter deal ‘temporarily on hold’
-
Middle East1 week agoJordan’s king issues decree restricting Prince Hamzah’s movement, communications
-
Movies2 weeks ago‘Doctor Strange 2’ holds top spot 2nd weekend in a row
-
Asia1 week agoTunnel collapses in India’s Kashmir region, workers trapped
